San Diego Marriott Del Mar
San Diego, CA
Biotechnology companies are increasingly using single-asset spinouts as a way to create value, though the approach can be complex. This afternoon forum will examine considerations to strategically design and execute a successful spinout. Attendees will gain insight into the legal foundations of these transactions, including tax considerations, patent strategy, IP allocation, and structural design. The program will also explore the broader business drivers behind spinout decisions—such as capital formation, strategic focus, partnership alignment, governance, and long-term value creation.
Featuring perspectives from Wilson Sonsini attorneys alongside investors, pharmaceutical leaders, and seasoned biotech executives, the forum will provide practical guidance on how spinouts are evaluated and implemented in today's market. Participants will leave with a clearer understanding of common challenges, lessons learned, and the critical early-stage decisions that support sustainable success.
This event is by invite only. To request an invitation, contact Kaela Japson.
Kaela Japson
kjapson@wsgr.com
Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.
Myra is a partner in the firm’s tax practice and represents clients in connection with federal income tax planning for a variety of corporate transactions in domestic and cross-border settings.
Jason represents companies at all stages of their life cycle, from start-ups to public companies.
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
Deborah Smith leads Wilson Sonsini’s Patents and Innovations practice in Southern California. She advises high-growth biotechnology and pharmaceutical companies and their investors on IP strategy across the full product lifecycle—from platform development through drug approval, commercialization, and exit—spanning modalities including small molecules, ADCs, degraders, molecular glues, peptides, nucleic acid therapeutics, biologics, and protein conjugates. Her work spans patent strategy, portfolio development, IP due diligence, and IP matters tied to regulatory approval, as well as transactional matters including buy-side and sell-side M&A, licensing, financings, IPOs, and reverse mergers.